Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment.

The aim of this study was to determine whether intravenously administered multipotent stromal cells from human bone marrow (hMSCs) can improve cardiac function after myocardial infarction (MI) without long-term engraftment and therefore whether transitory paracrine effects or secreted factors are responsible for the benefit conferred. hMSCs were injected systemically into immunodeficient mice with acute MI. Cardiac function and fibrosis after MI in the hMSC-treated group were significantly improved compared with controls. However, despite the cardiac improvement, there was no evident hMSC engraftment in the heart 3 weeks after MI. Microarray assays and ELISAs demonstrated that multiple protective factors were expressed and secreted from the hMSCs in culture. Factors secreted by hMSCs prevented cell death of cultured cardiomyocytes and endothelial cells under conditions that mimicked tissue ischemia. The favorable effects of hMSCs appear to reflect the impact of secreted factors rather than engraftment, differentiation, or cell fusion.

[1]  W. Vaughn,et al.  Mesenchymal Stem Cells Differentiate into an Endothelial Phenotype, Enhance Vascular Density, and Improve Heart Function in a Canine Chronic Ischemia Model , 2005, Circulation.

[2]  M. Ashraf,et al.  Implantation of bone marrow stem cells reduces the infarction and fibrosis in ischemic mouse heart. , 2003, Journal of molecular and cellular cardiology.

[3]  Phillip Nagley,et al.  Precise determination of mitochondrial DNA copy number in human skeletal and cardiac muscle by a PCR-based assay: lack of change of copy number with age. , 2003, Nucleic acids research.

[4]  Joshua M Hare,et al.  Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S. Ogawa,et al.  Cardiomyocytes can be generated from marrow stromal cells in vitro. , 1999, The Journal of clinical investigation.

[6]  Robert A. Kloner,et al.  Systemic Delivery of Bone Marrow–Derived Mesenchymal Stem Cells to the Infarcted Myocardium: Feasibility, Cell Migration, and Body Distribution , 2003, Circulation.

[7]  H. Ohgushi,et al.  Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. , 2004, American journal of physiology. Heart and circulatory physiology.

[8]  David A. Williams,et al.  Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts , 2004, Nature.

[9]  D. Prockop,et al.  One strategy for cell and gene therapy: Harnessing the power of adult stem cells to repair tissues , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Ross,et al.  Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress , 1999, Cell.

[11]  M. Burnett,et al.  Marrow-Derived Stromal Cells Express Genes Encoding a Broad Spectrum of Arteriogenic Cytokines and Promote In Vitro and In Vivo Arteriogenesis Through Paracrine Mechanisms , 2004, Circulation research.

[12]  H. Ben‐Hur,et al.  β2 Microglobulin-deficient (B2mnull) NOD/SCID mice are excellent recipients for studying human stem cell function , 2000 .

[13]  P. Anversa,et al.  bcl-2 overexpression promotes myocyte proliferation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  I. Weissman,et al.  Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium , 2004, Nature.

[15]  K. Alitalo,et al.  The biology of vascular endothelial growth factors. , 2005, Cardiovascular research.

[16]  J. Ingwall,et al.  Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells , 2005, Nature Medicine.

[17]  W. Wijns,et al.  Intracoronary Injection of CD133-Positive Enriched Bone Marrow Progenitor Cells Promotes Cardiac Recovery After Recent Myocardial Infarction: Feasibility and Safety , 2005, Circulation.

[18]  David M. Bodine,et al.  Bone marrow cells regenerate infarcted myocardium , 2001, Nature.

[19]  Joshua M. Hare,et al.  Is stem cell therapy ready for patients? Stem Cell Therapy for Cardiac Repair. Ready for the Next Step . , 2006, Circulation.

[20]  H. Ben‐Hur,et al.  beta2 microglobulin-deficient (B2m(null)) NOD/SCID mice are excellent recipients for studying human stem cell function. , 2000, Blood.

[21]  J. Ingwall,et al.  Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts , 2003, Nature Medicine.

[22]  A. Zeiher,et al.  ransplantation of Progenitor Cells nd Regeneration Enhancement n Acute Myocardial Infarction , 2004 .

[23]  C. Heeschen,et al.  Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. , 2005, Journal of molecular and cellular cardiology.

[24]  T. Jensen,et al.  Tissue distribution and engraftment of human mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene. , 2005, Biochemical and biophysical research communications.

[25]  Darwin J. Prockop,et al.  Mitochondrial transfer between cells can rescue aerobic respiration , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Ingwall,et al.  Evidence supporting paracrine hypothesis for Akt‐modified mesenchymal stem cell‐mediated cardiac protection and functional improvement , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  K. Mori,et al.  Adrenomedullin Infusion Attenuates Myocardial Ischemia/Reperfusion Injury Through the Phosphatidylinositol 3-Kinase/Akt-Dependent Pathway , 2004, Circulation.